^(125)I粒子植入联合化疗治疗非小细胞肺癌疗效观察

Clinical Efficacy of Interstitial Implantation of ^(125)I Seeds Combined with Chemotherapy in Patients with Non-small Cell Lung Carcinoma

探讨125I粒子联合化疗治疗非小细胞肺癌(NSCLC)的临床疗效。采用CT引导下肿瘤内植入125I粒子,3天后行长春瑞滨(NVB)和顺铂(DDP)静脉化疗,于2、4、6个月观察治疗效果(CR,PR,SD,PD)。结果表明125I粒子联合化疗组的有效率(CR+PR)分别为82.8%,90.6%,93.7%;单纯化疗组分别为44.3%,48.6%,52.9%,两组有显著性差异(P<0.05)。NSCLC行125I粒子联合化疗具有协同作用,有利于短期内减轻肿瘤负荷,提高肿瘤疗效。

To evaluate the clinical efficacy of 125I seed implantation combined with chemotherapy in the treatment of patients with non-small cell lung carcinoma（NSCLC）.The patients with NSCLC（n=64） were received interstitially 125I seed implantation by CT-guided,and then were treated with NVB and DDP after three days.In control group（n=70）,the patients were only treated with NVB and DDP.The therapeutic efficacy was observed after two,four and six months.The results showed that the effective rates（CR＋PR） after two,four and six months of the treatment were 82.8%,90.6%,93.7%,respectively.The effective rates in the control group were 4.4%,48.6%,52.9%,respectively.The therapeutic effects had significant difference between two groups（P0.05）.There was a synergistic effect between 125I seed implantation and chemotherapy in patients with NSCLC to reduce tumor load in a short period and improve the therapeutic efficacy.